Corvus Pharmaceuticals logo

Corvus Pharmaceuticals Share Price Today

(NASDAQ: CRVS)

Corvus Pharmaceuticals share price is $4.13 & ₹359.18 as on 6 Mar 2025, 2.30 'hrs' IST

$4.13

0.13

(3.25%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Corvus Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Corvus Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Corvus Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Corvus Pharmaceuticals share price movements

  • Today's Low: $3.99
    Today's High: $4.17

    Day's Volatility :4.44%

  • 52 Weeks Low: $1.30
    52 Weeks High: $10.00

    52 Weeks Volatility :87.0%

Corvus Pharmaceuticals (CRVS) Returns

PeriodCorvus Pharmaceuticals IncIndex (Russel 2000)
3 Months
-49.2%
0.0%
6 Months
3.25%
0.0%
1 Year
92.09%
0.0%
3 Years
164.74%
-11.6%

Corvus Pharmaceuticals (CRVS) Key Statistics

in dollars & INR

Previous Close
$4.0
Open
$4.0
Today's High
$4.17
Today's Low
$3.985
Market Capitalization
$257.0M
Today's Volume
$402.3K
52 Week High
$10.0
52 Week Low
$1.3
Revenue TTM
$0.0
EBITDA
$-25.0M
Earnings Per Share (EPS)
$-1.0
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-200.48%

How to invest in Corvus Pharmaceuticals Stock (CRVS) from India?

It is very easy for Indian residents to invest directly in Corvus Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Corvus Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Corvus Pharmaceuticals or CRVS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Corvus Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Corvus Pharmaceuticals shares which would translate to 0.211 fractional shares of Corvus Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Corvus Pharmaceuticals, in just a few clicks!

Returns in Corvus Pharmaceuticals (CRVS) for Indian investors in Rupees

The Corvus Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Corvus Pharmaceuticals investment value today

Current value as on today

₹1,97,042

Returns

₹97,042

(+97.04%)

Returns from Corvus Pharmaceuticals Stock

₹92,093 (+92.09%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Corvus Pharmaceuticals (CRVS)

-14%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Corvus Pharmaceuticals Stock from India on INDmoney has decreased by -14% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Corvus Pharmaceuticals

  • Orbimed Advisors, LLC

    10.81%

  • Samlyn Capital, LLC

    10.38%

  • Adams Street Partners LLC

    5.10%

  • Point72 Asset Management, L.P.

    4.72%

  • RTW INVESTMENTS, LLC

    4.17%

  • Vanguard Group Inc

    3.82%

Analyst Recommendation on Corvus Pharmaceuticals

Buy

    80%Buy

    20%Hold

    0%Sell

Based on 10 Wall street analysts offering stock ratings for Corvus Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Corvus Pharmaceuticals Stock (CRVS)

What analysts predicted

Upside of 258.35%

Target:

$14.80

Current:

$4.13

Insights on Corvus Pharmaceuticals Stock (Ticker Symbol: CRVS)

  • Price Movement

    In the last 7 days, CRVS stock has moved up by 4.8%

Corvus Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Corvus Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Corvus Pharmaceuticals (CRVS) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Corvus Pharmaceuticals Inc logo
-22.66%
3.25%
92.09%
164.74%
51.84%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Corvus Pharmaceuticals Inc logo
NA
NA
0.0
-0.92
-2.0
-0.28
NA
0.2
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Corvus Pharmaceuticals Inc logo
Buy
$257.0M
51.84%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
Organization
Corvus Pharmaceuticals
Employees
28
CEO
Dr. Richard A. Miller M.D.
Industry
Health Technology

Management People of Corvus Pharmaceuticals

NameTitle
Dr. Richard A. Miller M.D.
Co-Founder, President, CEO & Chairman of the Board
Dr. Peter A. Thompson FACP, M.D.
Co-Founder & Independent Director
Mr. Leiv Lea
Chief Financial Officer
Dr. William Benton Jones Ph.D.
Senior Vice President of Pharmaceutical Development
Mr. Jeffrey S. Arcara
Chief Business Officer

Important FAQs about investing in CRVS Stock from India :

What is Corvus Pharmaceuticals share price today?

Corvus Pharmaceuticals share price today stands at $4.13, Open: $4.00 ; Previous Close: $4.00 ; High: $4.17 ; Low: $3.99 ; 52 Week High: $10.00 ; 52 Week Low: $1.30.

The stock opens at $4.00, after a previous close of $4.00. The stock reached a daily high of $4.17 and a low of $3.99, with a 52-week high of $10.00 and a 52-week low of $1.30.

Can Indians buy Corvus Pharmaceuticals shares?

Yes, Indians can invest in the Corvus Pharmaceuticals (CRVS) from India.

With INDmoney, you can buy Corvus Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Corvus Pharmaceuticals at zero transaction cost.

How can I buy Corvus Pharmaceuticals shares from India?

It is very easy to buy Corvus Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Corvus Pharmaceuticals (CRVS) be purchased?

Yes, you can buy fractional shares of Corvus Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Corvus Pharmaceuticals stocks?

To start investing in Corvus Pharmaceuticals, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Corvus Pharmaceuticals Stock (CRVS)?

Today’s highest price of Corvus Pharmaceuticals (CRVS) is $4.17.

Today’s lowest price of Corvus Pharmaceuticals (CRVS) is $3.99.

What is today's market capitalisation of Corvus Pharmaceuticals?

Today's market capitalisation of Corvus Pharmaceuticals CRVS is 257.0M

What is the 52 Week High and Low Range of Corvus Pharmaceuticals Stock (CRVS)?

  • 52 Week High

    $10.00

  • 52 Week Low

    $1.30

What are the historical returns of Corvus Pharmaceuticals (CRVS)?

  • 1 Month Returns

    -22.66%

  • 3 Months Returns

    3.25%

  • 1 Year Returns

    92.09%

  • 5 Years Returns

    51.84%

Who is the Chief Executive Officer (CEO) of Corvus Pharmaceuticals ?

Dr. Richard A. Miller M.D. is the current Chief Executive Officer (CEO) of Corvus Pharmaceuticals.